Joris Deelen, PhD, is a Research Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany. His research group focuses on studying the genetic mechanisms underlying healthy ageing in humans, particularly investigating the effect of unique genetic variants in long-lived individuals on pathways related to ageing and age-related diseases. They also work on identifying and validating biomarkers of healthy ageing through large-scale international collaborations.
Joris Deelen’s scientific career includes postdoctoral research in Biological Mechanisms of Ageing at the Max Planck Institute for Biology of Ageing and Molecular Epidemiology at Leiden University Medical Center. He holds a Doctor of Philosophy (PhD) in Molecular Epidemiology from Leiden University, where his thesis was on “Genetic and biomarker studies of human longevity”.
Dr. Deelen is also a Principal Investigator at CECAD (Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases) in Cologne[4]. His expertise lies in genetics and biomarkers of human ageing, contributing significantly to the understanding of why some individuals age more healthily than others.